Fulcrum plummets 50% after scrapping lead sickle-cell drug on FDA concerns
Shares of Fulcrum Therapeutics plunged 50% in premarket trading on Tuesday after the company said it would abandon development of its experimental sickle-cell disease drug following
June 02, 2026
Construction begins on George Floyd Square redevelopment
New gym opening uses AI to help people rethink their workout
Rancher offers reward as Utah County deputies work to solve cattle theft
Stabbing suspect due in court after night of anti-immigrant protests in Northern Ireland
Fear of Ukrainian drones empties the guesthouses in Latvia's Land of Blue Lakes
Greece approves quicker migrant returns, aims to set up return hubs
India bond-tax moves to catalyse foreign debt inflows, bolster bid for global index inclusion
Honda America recalls more than 880,000 vehicles over rear suspension components failure
Somali World Cup referee denied entry to US arrives home to hero's welcome